Login to Your Account



Serono Signs On Graffinity As Partner For Drug Development

By Douglas Merrill


Friday, April 4, 2003
Graffinity AG, a specialist in preclinical drug discovery, landed a commitment from Serono SA to help fill the development pipeline of Europe's largest biotechnology company. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription